Efficacy and Safety of Cagrilintide Alone and in Combination with Semaglutide (Cagrisema) as Anti-Obesity Medications: A Systematic Review and Meta-Analysis

Dec 16, 2024Indian journal of endocrinology and metabolism

Effectiveness and Safety of Cagrilintide Alone and with Semaglutide as Weight-Loss Medications

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗

Abstract

Cagrisema resulted in a 9.07% greater percentage weight loss compared to semaglutide after 20-32 weeks.

Data from 3 randomized controlled trials involving 430 obese individuals were analyzed.
Patients receiving Cagrisema experienced an absolute weight loss of 9.11 kg compared to semaglutide.
Cagrilintide 2.4 mg showed a similar percentage weight loss to semaglutide/liraglutide, but results were not statistically significant.
Gastrointestinal adverse events were more frequent with Cagrisema than with semaglutide.
Vomiting was significantly less common with cagrilintide compared to semaglutide/liraglutide.
Overall, Cagrisema may be more effective for weight loss than semaglutide.

AI simplified

No meta-analysis has analysed role of cagrilintide as weight-loss medication in obese individuals. Electronic databases were searched for RCTs involving obese individuals receiving cagrilintide or cagrilintide-2.4 mg with semaglutide-2.4 mg combination (Cagrisema) compared to placebo/active comparator. Primary outcomes were changes in body weight; secondary outcomes were alterations in glycemia, lipids, and adverse events. From 678 articles, data from 3 RCTs involving 430 individuals were analysed. At 20-32 weeks, patients receiving Cagrisema weekly had significantly greater percentage [mean difference (MD)-9.07% (95%CI: -11.91, -6.23);< 0.00001;= 96%] and absolute [MD-9.11 kg (95%CI: -12.84, -5.39);< 0.00001;= 98%] weight-loss, compared to semaglutide 2.4 mg weekly. At 26-32 weeks, cagrilintide 2.4 mg had a similar percentage [MD - 1.83% (95%CI: -4.08, -0.42);= 0.11;= 98%] and absolute [MD - 1.88 kg (95%CI: -4.23,0.47);= 0.12;= 98%] weight-loss, compared to semaglutide/liraglutide. Treatment-emergent and serious adverse events were comparable between groups. Gastrointestinal adverse events and vomiting were significantly higher with Cagrisema compared to semaglutide. Vomiting was significantly lower with cagrilintide compared to semaglutide/liraglutide. Cagrisema outperforms semaglutide regarding weight loss. Cagrilintide shows comparable weight loss to semaglutide/liraglutide with significantly lower vomiting. P I P I P I P I2 2 2 2

Full Text

We can’t show the full text here under this license. Use the link below to read it at the source.

View full text ↗

Efficacy and Safety of Cagrilintide Alone and in Combination with Semaglutide (Cagrisema) as Anti-Obesity Medications: A Systematic Review and Meta-Analysis

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief